首页 > 最新文献

Cvd Prevention and Control最新文献

英文 中文
Proceedings from the workshop on estimating the contributions of sodium reduction to preventable death 估计减少钠对可预防死亡的贡献研讨会论文集
Pub Date : 2011-06-01 DOI: 10.1016/j.cvdpc.2011.02.003
Steven M. Schmidt , Talley Andrews , Kirsten Bibbins-Domingo , Vicki Burt , Nancy R. Cook , Majid Ezzati , Johanna M. Geleijnse , Jack Homer , Michel Joffres , Nora L. Keenan , Darwin R. Labarthe , Malcolm Law , Catherine M. Loria , Diane Orenstein , Michael W. Schooley , Seetha Sukumar , Yuling Hong

The primary goal of this workshop was to identify the most appropriate method to estimate the potential effect of reduction in sodium consumption on mortality. Difficulty controlling hypertension at the individual level has motivated international, federal, state, and local efforts to identify and implement population-wide strategies to better control this problem; reduction of sodium intake is one such strategy. Published estimates of the impact of sodium consumption on mortality have used different modeling approaches, effect sizes, and levels of sodium consumption, and thus their estimates of preventable deaths averted vary widely, and are not comparable. In response to this problem, the Centers for Disease Control and Prevention’s Division for Heart Disease and Stroke Prevention (DHDSP) convened and facilitated a workshop to examine different methods of estimating the effect of sodium reduction on mortality. The panelists agreed that any of the methodologies presented could provide reasonable estimates, and therefore discussion focused on challenges faced by all methods. The panel concluded that future sodium modeling efforts should generate multiple estimates employing the same scenarios and effect sizes while using different modeling techniques; in addition, future efforts should include outcomes other than mortality (morbidity, costs, and quality of life). Varying reductions in sodium should be modeled at the population level over different time intervals. In an effort to better address some of the uncertainties highlighted by this workshop, the panelists are currently considering developing multiple estimates in a collaborative manner to clarify the potential impact of population-based interventions to reduce sodium consumption.

本次研讨会的主要目标是确定最适当的方法来估计减少钠摄入量对死亡率的潜在影响。在个人层面控制高血压的困难促使国际、联邦、州和地方努力确定和实施全民战略,以更好地控制这一问题;减少钠的摄入就是这样一种策略。已发表的关于钠消费对死亡率影响的估计使用了不同的建模方法、效应大小和钠消费水平,因此它们对避免的可预防死亡的估计差异很大,不具有可比性。针对这一问题,美国疾病控制和预防中心心脏病和中风预防部(DHDSP)召集并推动了一次研讨会,以研究估算钠摄入量减少对死亡率影响的不同方法。小组成员一致认为,所提出的任何方法都可以提供合理的估计,因此讨论的重点是所有方法面临的挑战。该小组的结论是,未来的钠模拟工作应该在使用不同建模技术的同时,采用相同的情景和效应大小,得出多个估计;此外,未来的努力应包括死亡率以外的结果(发病率、费用和生活质量)。钠的减少应该在不同的时间间隔内以人群水平为模型。为了更好地解决本次研讨会强调的一些不确定性,小组成员目前正在考虑以合作的方式制定多种评估,以阐明以人群为基础的干预措施对减少钠消费的潜在影响。
{"title":"Proceedings from the workshop on estimating the contributions of sodium reduction to preventable death","authors":"Steven M. Schmidt ,&nbsp;Talley Andrews ,&nbsp;Kirsten Bibbins-Domingo ,&nbsp;Vicki Burt ,&nbsp;Nancy R. Cook ,&nbsp;Majid Ezzati ,&nbsp;Johanna M. Geleijnse ,&nbsp;Jack Homer ,&nbsp;Michel Joffres ,&nbsp;Nora L. Keenan ,&nbsp;Darwin R. Labarthe ,&nbsp;Malcolm Law ,&nbsp;Catherine M. Loria ,&nbsp;Diane Orenstein ,&nbsp;Michael W. Schooley ,&nbsp;Seetha Sukumar ,&nbsp;Yuling Hong","doi":"10.1016/j.cvdpc.2011.02.003","DOIUrl":"10.1016/j.cvdpc.2011.02.003","url":null,"abstract":"<div><p>The primary goal of this workshop was to identify the most appropriate method to estimate the potential effect of reduction in sodium consumption on mortality. Difficulty controlling hypertension at the individual level has motivated international, federal, state, and local efforts to identify and implement population-wide strategies to better control this problem; reduction of sodium intake is one such strategy. Published estimates of the impact of sodium consumption on mortality have used different modeling approaches, effect sizes, and levels of sodium consumption, and thus their estimates of preventable deaths averted vary widely, and are not comparable. In response to this problem, the Centers for Disease Control and Prevention’s Division for Heart Disease and Stroke Prevention (DHDSP) convened and facilitated a workshop to examine different methods of estimating the effect of sodium reduction on mortality. The panelists agreed that any of the methodologies presented could provide reasonable estimates, and therefore discussion focused on challenges faced by all methods. The panel concluded that future sodium modeling efforts should generate multiple estimates employing the same scenarios and effect sizes while using different modeling techniques; in addition, future efforts should include outcomes other than mortality (morbidity, costs, and quality of life). Varying reductions in sodium should be modeled at the population level over different time intervals. In an effort to better address some of the uncertainties highlighted by this workshop, the panelists are currently considering developing multiple estimates in a collaborative manner to clarify the potential impact of population-based interventions to reduce sodium consumption.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 2","pages":"Pages 35-40"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2011.02.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77801345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Corrigendum to ‘Gamma-Glutamyltransferase and mortality risk from heart disease and stroke in Japanese men and women: NIPPON DATA 90’ “γ -谷氨酰转移酶与日本男性和女性心脏病和中风的死亡风险:NIPPON DATA 90”的勘误表
Pub Date : 2011-06-01 DOI: 10.1016/j.cvdpc.2011.02.002
Akira Fujiyoshi , Katsuyuki Miura , Atsushi Hozawa , Yoshitaka Murakami , Naoyuki Takashima , Nagako Okuda , Takashi Kadowaki , Yoshikuni Kita , Tomonori Okamura , Yasuyuki Nakamura , Takehito Hayakawa , Akira Okayama , Hirotsugu Ueshima , for the NIPPON DATA80/90 Research Group
{"title":"Corrigendum to ‘Gamma-Glutamyltransferase and mortality risk from heart disease and stroke in Japanese men and women: NIPPON DATA 90’","authors":"Akira Fujiyoshi ,&nbsp;Katsuyuki Miura ,&nbsp;Atsushi Hozawa ,&nbsp;Yoshitaka Murakami ,&nbsp;Naoyuki Takashima ,&nbsp;Nagako Okuda ,&nbsp;Takashi Kadowaki ,&nbsp;Yoshikuni Kita ,&nbsp;Tomonori Okamura ,&nbsp;Yasuyuki Nakamura ,&nbsp;Takehito Hayakawa ,&nbsp;Akira Okayama ,&nbsp;Hirotsugu Ueshima ,&nbsp;for the NIPPON DATA80/90 Research Group","doi":"10.1016/j.cvdpc.2011.02.002","DOIUrl":"10.1016/j.cvdpc.2011.02.002","url":null,"abstract":"","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 2","pages":"Page 63"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2011.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85481773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoantibodies against cardiac troponin I in patients presenting with myocarditis 心肌炎患者抗心肌肌钙蛋白I的自身抗体
Pub Date : 2011-06-01 DOI: 10.1016/j.cvdpc.2011.02.004
Akira Matsumori , Toshio Shimada , Hiroaki Hattori , Miho Shimada , Jay W. Mason

Background

Autoantibodies against cardiac troponin I (cTnI) play an important role in the pathogenesis of experimental cardiomyopathy. We developed a new method to measure anti-cardiac troponin I autoantibody (Anti-cTnIAAB) in patients with myocarditis with or without HCV infection.

Methods

Patients with heart failure for up to 2 years, without a distinct cause, were enrolled in the Myocarditis Treatment Trial between 1986 and 1990. Frozen blood samples were available from 1315 to 2233 enrolled patients. Anti-cTnIAAB was determined by a two-step immunoassay.

Results

The mean (±SEM) value of serum Anti-cTnIAAB titer in the 1315 patients was 0.067 ± 0.003 arbitrary unit (AU), significantly higher than in 1115 healthy volunteers (0.053 ± 0.002 AU, P < 0.01). The mean Anti-cTnIAAB titer in 88 patients whose endomyocardial biopsies (EMB) satisfied the diagnostic Dallas criteria was 0.086 ± 0.010 AU, versus 0.066 ± 0.004 AU in 1227 patients whose EMB did not satisfy these criteria. The mean Anti-cTnIAAB in both groups was significantly higher than that measured in the healthy volunteers (P < 0.01). The mean Anti-cTnIAAB titer in the 88 patients with Dallas criteria-confirmed myocarditis tended to be higher than in the other 1227 patients. Among the 88 patients with Dallas criteria-confirmed myocarditis, the mean Anti-cTnIAAB titer in 5 patients infected with the hepatitis C virus infection (HCV) was significantly higher (0.146 ± 0.047 AU) than in 83 patients without HCV infection (0.082 ± 0.010 AU, P < 0.05).

Conclusions

Elevated autoantibody titers against cTnI were detected in patients with myocarditis, and were higher in HCV-infected patients. The presence of Anti-cTnIAAB might correlate with inflammation and viral infection of the heart.

背景:抗心肌肌钙蛋白I (cTnI)的自身抗体在实验性心肌病的发病机制中起重要作用。我们开发了一种新的方法来检测伴有或不伴有HCV感染的心肌炎患者的抗心肌肌钙蛋白I自身抗体(Anti-cTnIAAB)。方法1986年至1990年心肌炎治疗试验纳入了无明显原因的心力衰竭患者,时间长达2年。冷冻血液样本来自1315至2233名入组患者。采用两步免疫分析法检测抗ctniaab。结果1315例患者血清抗ctniaab滴度平均值(±SEM)为0.067±0.003任意单位(AU),显著高于1115例健康志愿者(0.053±0.002 AU, P <0.01)。88例心内膜肌活检(EMB)符合达拉斯诊断标准的患者的平均抗ctniaab滴度为0.086±0.010 AU,而1227例EMB不符合这些标准的患者的平均抗ctniaab滴度为0.066±0.004 AU。两组的Anti-cTnIAAB平均值均显著高于健康志愿者(P <0.01)。88例达拉斯标准确诊心肌炎患者的平均抗ctniaab滴度倾向于高于其他1227例患者。在88例达拉斯标准确诊的心肌炎患者中,5例丙型肝炎病毒感染(HCV)患者的Anti-cTnIAAB平均滴度(0.146±0.047 AU)显著高于83例非HCV感染患者(0.082±0.010 AU), P <0.05)。结论心肌炎患者血清cTnI抗体水平升高,hcv感染患者血清cTnI抗体水平较高。抗ctniaab的存在可能与心脏的炎症和病毒感染有关。
{"title":"Autoantibodies against cardiac troponin I in patients presenting with myocarditis","authors":"Akira Matsumori ,&nbsp;Toshio Shimada ,&nbsp;Hiroaki Hattori ,&nbsp;Miho Shimada ,&nbsp;Jay W. Mason","doi":"10.1016/j.cvdpc.2011.02.004","DOIUrl":"10.1016/j.cvdpc.2011.02.004","url":null,"abstract":"<div><h3>Background</h3><p>Autoantibodies against cardiac troponin I (cTnI) play an important role in the pathogenesis of experimental cardiomyopathy. We developed a new method to measure anti-cardiac troponin I autoantibody (Anti-cTnIAAB) in patients with myocarditis with or without HCV infection.</p></div><div><h3>Methods</h3><p>Patients with heart failure for up to 2<!--> <!-->years, without a distinct cause, were enrolled in the Myocarditis Treatment Trial between 1986 and 1990. Frozen blood samples were available from 1315 to 2233 enrolled patients. Anti-cTnIAAB was determined by a two-step immunoassay.</p></div><div><h3>Results</h3><p>The mean (±SEM) value of serum Anti-cTnIAAB titer in the 1315 patients was 0.067<!--> <!-->±<!--> <!-->0.003 arbitrary unit (AU), significantly higher than in 1115 healthy volunteers (0.053<!--> <!-->±<!--> <!-->0.002 AU, <em>P</em> <!-->&lt;<!--> <!-->0.01). The mean Anti-cTnIAAB titer in 88 patients whose endomyocardial biopsies (EMB) satisfied the diagnostic Dallas criteria was 0.086<!--> <!-->±<!--> <!-->0.010 AU, versus 0.066<!--> <!-->±<!--> <!-->0.004 AU in 1227 patients whose EMB did not satisfy these criteria. The mean Anti-cTnIAAB in both groups was significantly higher than that measured in the healthy volunteers (<em>P</em> <!-->&lt;<!--> <!-->0.01). The mean Anti-cTnIAAB titer in the 88 patients with Dallas criteria-confirmed myocarditis tended to be higher than in the other 1227 patients. Among the 88 patients with Dallas criteria-confirmed myocarditis, the mean Anti-cTnIAAB titer in 5 patients infected with the hepatitis C virus infection (HCV) was significantly higher (0.146<!--> <!-->±<!--> <!-->0.047 AU) than in 83 patients without HCV infection (0.082<!--> <!-->±<!--> <!-->0.010 AU, <em>P</em> <!-->&lt;<!--> <!-->0.05).</p></div><div><h3>Conclusions</h3><p>Elevated autoantibody titers against cTnI were detected in patients with myocarditis, and were higher in HCV-infected patients. The presence of Anti-cTnIAAB might correlate with inflammation and viral infection of the heart.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 2","pages":"Pages 41-46"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2011.02.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73858074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Highlights of the first Malaysian National Cardiovascular Disease Database (NCVD): Percutaneous Coronary Intervention (PCI) Registry 首个马来西亚国家心血管疾病数据库(NCVD)的亮点:经皮冠状动脉介入治疗(PCI)登记
Pub Date : 2011-06-01 DOI: 10.1016/j.cvdpc.2011.02.006
Wan Azman Wan Ahmad , Rosli Mohd Ali , Robaayah Zambahari , Omar Ismail , Lee Chuey Yan , Liew Houng Bang , Chee Kok Han , Sim Kui Hian

Objective

The Malaysian NCVD-PCI registry attempts to determine the number and to monitor the outcomes of Percutaneous Coronary Intervention (PCI), based on selected performance indicators. It provides a comprehensive view to determine the level of adherence to existing guidelines, to evaluate the cost-effectiveness of treatment and prevention programs and to facilitate quality improvement activities of the participants. It also aims to stimulate research and to act as a reference for future studies.

Methods

It was a voluntary, multi-centered, observational, cohort study and included patients of 18 years or above, with coronary artery disease who underwent PCI at eight participating centers in the year 2007.

Results

A total of 3677 patients underwent 3920 PCI procedures with 6299 stents for 5512 lesions. The mean age of patients was 56.7 ± 10.11 years. The mean BMI was 26.38 ± 4.21 kg/m2, while 80% of all subjects had a BMI above 23 kg/m2. Males constituted 81.2% of the total population and 98.4% of the total population had at least one cardiovascular risk factor. Regarding PCI status, 90.1% were elective cases and 94% of cases had a low TIMI risk index at the beginning of PCI. Femoral approach accounted for 59%, radial approach for 34% and brachial approach for 1% of all cases. The median fluoroscopy time was 15.7 min and the median door-to-balloon time for primary infarct PCI was 93.5 min. The commonest site of lesion was the left anterior descending artery, accounting for 48% of all lesions and 92.8% of all lesions were de novo. The mean lesion length was 24.4 ± 15.18 mm and about 28% of all lesions had high risk characteristics. Drug-eluting stents and bare metal stents were used in 53.6% and 42.5% of cases, respectively. After PCI, 91% of all lesions achieved TIMI grade 3 flow. Regarding pharmacotherapy, 99.5% of all patients received unfractionated heparin, 5% received LMWH prior to intervention, 96% received aspirin and 98% received clopidogrel. Over-all in-hospital mortality and 30 day mortality for the entire cohort was 1.1% and 1.8%, respectively.

Conclusion

A summary of the first nationwide PCI registry has been presented. The subjects were much younger with a high prevalence of cardiovascular risk factors. The majority of cases (90%) were elective procedures with a low TIMI risk index. Mean door-to-balloon time for primary PCI was higher than the recommended guidelines. There was good prescribing of antiplatelets and heparin. Over-all in-hospital and 30 day mortality were comparable to other registries.

目的马来西亚ncd -PCI登记处试图根据选定的性能指标确定经皮冠状动脉介入治疗(PCI)的数量和监测结果。它提供了一个全面的观点来确定对现有指导方针的遵守程度,评估治疗和预防方案的成本效益,并促进参与者的质量改进活动。它还旨在刺激研究,并为未来的研究提供参考。该研究是一项自愿、多中心、观察性、队列研究,纳入了2007年在8个参与中心接受PCI治疗的18岁及以上冠状动脉疾病患者。结果共3677例患者接受了3920次PCI手术,植入支架6299个,病变5512个。患者平均年龄56.7±10.11岁。平均BMI为26.38±4.21 kg/m2, 80%的受试者BMI大于23 kg/m2。男性占总人口的81.2%,其中98.4%的人至少有一种心血管危险因素。在PCI状态方面,90.1%为选择性病例,94%的病例在PCI开始时TIMI风险指数较低。股骨入路占59%,桡骨入路占34%,肱入路占1%。原发性梗死PCI的中位透视时间为15.7 min,门到球囊的中位时间为93.5 min。病变最常见的部位为左前降支,占所有病变的48%,92.8%为新发病变。平均病变长度为24.4±15.18 mm,约28%的病变具有高危特征。药物洗脱支架和裸金属支架分别占53.6%和42.5%。PCI后,91%的病灶达到TIMI 3级血流。在药物治疗方面,99.5%的患者在干预前接受未分割肝素治疗,5%接受低分子肝素治疗,96%接受阿司匹林治疗,98%接受氯吡格雷治疗。整个队列的总体住院死亡率和30天死亡率分别为1.1%和1.8%。结论第一个全国性PCI登记的摘要已经被提出。研究对象年龄更小,心血管危险因素的患病率更高。大多数病例(90%)为选择性手术,TIMI风险指数较低。初次PCI的平均门到球囊时间高于推荐指南。抗血小板和肝素处方良好。总体住院死亡率和30天死亡率与其他登记数据相当。
{"title":"Highlights of the first Malaysian National Cardiovascular Disease Database (NCVD): Percutaneous Coronary Intervention (PCI) Registry","authors":"Wan Azman Wan Ahmad ,&nbsp;Rosli Mohd Ali ,&nbsp;Robaayah Zambahari ,&nbsp;Omar Ismail ,&nbsp;Lee Chuey Yan ,&nbsp;Liew Houng Bang ,&nbsp;Chee Kok Han ,&nbsp;Sim Kui Hian","doi":"10.1016/j.cvdpc.2011.02.006","DOIUrl":"10.1016/j.cvdpc.2011.02.006","url":null,"abstract":"<div><h3>Objective</h3><p>The Malaysian NCVD-PCI registry attempts to determine the number and to monitor the outcomes of Percutaneous Coronary Intervention (PCI), based on selected performance indicators. It provides a comprehensive view to determine the level of adherence to existing guidelines, to evaluate the cost-effectiveness of treatment and prevention programs and to facilitate quality improvement activities of the participants. It also aims to stimulate research and to act as a reference for future studies.</p></div><div><h3>Methods</h3><p>It was a voluntary, multi-centered, observational, cohort study and included patients of 18<!--> <!-->years or above, with coronary artery disease who underwent PCI at eight participating centers in the year 2007.</p></div><div><h3>Results</h3><p>A total of 3677 patients underwent 3920 PCI procedures with 6299 stents for 5512 lesions. The mean age of patients was 56.7<!--> <!-->±<!--> <!-->10.11<!--> <!-->years. The mean BMI was 26.38<!--> <!-->±<!--> <!-->4.21<!--> <!-->kg/m<sup>2</sup>, while 80% of all subjects had a BMI above 23<!--> <!-->kg/m<sup>2</sup>. Males constituted 81.2% of the total population and 98.4% of the total population had at least one cardiovascular risk factor. Regarding PCI status, 90.1% were elective cases and 94% of cases had a low TIMI risk index at the beginning of PCI. Femoral approach accounted for 59%, radial approach for 34% and brachial approach for 1% of all cases. The median fluoroscopy time was 15.7<!--> <!-->min and the median door-to-balloon time for primary infarct PCI was 93.5<!--> <!-->min. The commonest site of lesion was the left anterior descending artery, accounting for 48% of all lesions and 92.8% of all lesions were de novo. The mean lesion length was 24.4<!--> <!-->±<!--> <!-->15.18<!--> <!-->mm and about 28% of all lesions had high risk characteristics. Drug-eluting stents and bare metal stents were used in 53.6% and 42.5% of cases, respectively. After PCI, 91% of all lesions achieved TIMI grade 3 flow. Regarding pharmacotherapy, 99.5% of all patients received unfractionated heparin, 5% received LMWH prior to intervention, 96% received aspirin and 98% received clopidogrel. Over-all in-hospital mortality and 30<!--> <!-->day mortality for the entire cohort was 1.1% and 1.8%, respectively.</p></div><div><h3>Conclusion</h3><p>A summary of the first nationwide PCI registry has been presented. The subjects were much younger with a high prevalence of cardiovascular risk factors. The majority of cases (90%) were elective procedures with a low TIMI risk index. Mean door-to-balloon time for primary PCI was higher than the recommended guidelines. There was good prescribing of antiplatelets and heparin. Over-all in-hospital and 30<!--> <!-->day mortality were comparable to other registries.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 2","pages":"Pages 57-61"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2011.02.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82482137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Community Interventions for Health (CIH): A novel approach to tackling the worldwide epidemic of chronic diseases 社区健康干预(CIH):一种解决全球慢性病流行的新方法
Pub Date : 2011-06-01 DOI: 10.1016/j.cvdpc.2011.02.005
Kathleen O’Connor Duffany , Diane T. Finegood , David Matthews , Martin McKee , K.M. Venkat Narayan , Pekka Puska , Karen Siegel , Denise Stevens , Fiona Wong , Mark Woodward , Derek Yach

Community Interventions for Health (CIH) is a 3 year pilot study focusing on testing chronic disease prevention activities in developing country settings. CIH uses structural interventions and community mobilization, supported by health education and social marketing/media. The activities of CIH are pervasive throughout defined community settings using schools, work places, health care settings, and the community at large to create sustainable change. CIH seeks to: (1) assess the impact of the interventions on individuals and on the community, (2) assess the best methods for intervention implementation, (3) identify adaptations needed for global replication, and (4) identify community-specific barriers and facilitators to change. Additionally, the CIH study provides the larger medical and public health community with research and evaluation tools and methodology, including context assessment manuals, environmental scan tools and processes, and adaptations for developing country settings. CIH is building a large dataset of common measures across countries that may be used to inform local and national policies and practices. The purpose of this paper is to present the results of a several year planning process that includes a theoretical framework and study design that highlights the key elements of conducting complex community interventions in developing country settings.

社区卫生干预(CIH)是一项为期3年的试点研究,重点是在发展中国家环境中测试慢性病预防活动。社区卫生保健在卫生教育和社会营销/媒体的支持下,采用结构性干预措施和社区动员。CIH的活动遍及学校、工作场所、卫生保健机构和整个社区,以创造可持续的变化。CIH寻求:(1)评估干预措施对个人和社区的影响;(2)评估实施干预措施的最佳方法;(3)确定全球复制所需的适应措施;(4)确定社区特有的变革障碍和促进因素。此外,CIH研究为更大的医疗和公共卫生界提供了研究和评价工具和方法,包括背景评估手册、环境扫描工具和程序,以及针对发展中国家环境的调整。CIH正在建立各国共同措施的大型数据集,可用于为地方和国家政策和实践提供信息。本文的目的是介绍几年规划过程的结果,其中包括一个理论框架和研究设计,突出了在发展中国家环境中进行复杂社区干预的关键要素。
{"title":"Community Interventions for Health (CIH): A novel approach to tackling the worldwide epidemic of chronic diseases","authors":"Kathleen O’Connor Duffany ,&nbsp;Diane T. Finegood ,&nbsp;David Matthews ,&nbsp;Martin McKee ,&nbsp;K.M. Venkat Narayan ,&nbsp;Pekka Puska ,&nbsp;Karen Siegel ,&nbsp;Denise Stevens ,&nbsp;Fiona Wong ,&nbsp;Mark Woodward ,&nbsp;Derek Yach","doi":"10.1016/j.cvdpc.2011.02.005","DOIUrl":"10.1016/j.cvdpc.2011.02.005","url":null,"abstract":"<div><p>Community Interventions for Health (CIH) is a 3<!--> <!-->year pilot study focusing on testing chronic disease prevention activities in developing country settings. CIH uses structural interventions and community mobilization, supported by health education and social marketing/media. The activities of CIH are pervasive throughout defined community settings using schools, work places, health care settings, and the community at large to create sustainable change. CIH seeks to: (1) assess the impact of the interventions on individuals and on the community, (2) assess the best methods for intervention implementation, (3) identify adaptations needed for global replication, and (4) identify community-specific barriers and facilitators to change. Additionally, the CIH study provides the larger medical and public health community with research and evaluation tools and methodology, including context assessment manuals, environmental scan tools and processes, and adaptations for developing country settings. CIH is building a large dataset of common measures across countries that may be used to inform local and national policies and practices. The purpose of this paper is to present the results of a several year planning process that includes a theoretical framework and study design that highlights the key elements of conducting complex community interventions in developing country settings.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 2","pages":"Pages 47-56"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2011.02.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82572296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 49
Remote preconditioning by aortic constriction: Does it afford cardioprotection similar to classical or other remote ischaemic preconditioning? Role of inducible nitric oxide synthase 通过主动脉收缩进行远程预适应:它是否提供类似于经典或其他远程缺血预适应的心脏保护?诱导型一氧化氮合酶的作用
Pub Date : 2011-01-01 DOI: 10.1016/j.cvdpc.2010.12.001
Ashish Kumar Sharma , Arshee Munajjam , Bhawna Vaishnav , Richa Sharma , Kunal Kishore , Ashok Sharma , Akash Sharma , Divya Sharma , Rita Kumari , Ashish Tiwari , B.P. Srinivasan , Shyam Sunder Agarwal

Purpose of the research

Does remote preconditioning by aortic constriction (RPAC) afford cardioprotection similar to classical or other remote ischaemic preconditioning stimulus? Moreover, the study was also designed to investigate the role of inducible nitric oxide synthase (iNOS) in remote preconditioning by aortic constriction. There are sufficient evidence that ‘ischaemic preconditioning’ has surgical applications and affords clinically relevant cardioprotection. Transient occlusion of the circumflex artery, renal artery, limb artery or mesenteric artery preconditions the myocardium against ischaemia/reperfusion injury in case of ischaemic heart disease leading to myocardial infarction. Here, the abdominal aorta was selected to produce RPAC.

The principal results

Four episodes of ischaemia/reperfusion of 5 min each to the abdominal aorta produced RPAC by assessment of infarct size, lactate dehydrogenase (LDH) and creatine phosphokinase (CK). These studies suggest RPAC produced acute (FWOP) and delayed (SWOP) cardioprotective effects. RPAC demonstrated a significant decrease in ischaemia/reperfusion-induced release of LDH, CK and extent of myocardial infarct size. l-NAME (nitro-l-arginine-methylester) (10 mg kg−1 I.V.), aminoguanidine (150 mg kg−1 s.c.), aminoguanidine (300 mg kg−1 s.c.), S-methyl isothiourea (3 mg kg−1 I.V.) and 1400W (1 mg kg−1 I.V.) administered 10 min. before global ischaemia/reperfusion produced no marked effect. Aminoguanidine (150 mg kg−1 s.c.), aminoguanidine (300 mg kg−1 s.c.), S-methyl isothiourea (3 mg kg−1 I.V.) and 1400W (1 mg kg−1 I.V.) pre-treatment after RPAC produced no significant effect on acute RPAC-induced decrease in LDH, CK and infarct size, whereas l-NAME (10 mg kg−1 I.V.) increased RPAC-induced decrease in LDH, CK and infarct size. The most interesting observation is with respect to delayed RPAC, where all NOS inhibitors’ pre-treatment attenuate RPAC-induced decrease in LDH, CK and infarct size.

Major conclusions

RPAC affords cardioprotection similar to classical or other remote ischaemic preconditioning stimulus. Moreover, late or delayed phase of RPAC has been mediated iNOS, whereas it is not involved in acute RPAC.

研究目的:通过主动脉收缩(RPAC)进行的远程预适应是否提供与经典或其他远程缺血预适应刺激相似的心脏保护?此外,本研究还旨在探讨诱导型一氧化氮合酶(iNOS)在主动脉收缩远程预适应中的作用。有足够的证据表明,“缺血预处理”有外科应用,并提供临床相关的心脏保护。在缺血性心脏病导致心肌梗死的情况下,旋动脉、肾动脉、肢体动脉或肠系膜动脉的短暂闭塞为心肌抗缺血/再灌注损伤提供了先决条件。在这里,选择腹主动脉产生RPAC。主要结果:通过评估梗死面积、乳酸脱氢酶(LDH)和肌酸磷酸激酶(CK),腹腔主动脉缺血/再灌注4次,每次5分钟产生RPAC。这些研究表明RPAC具有急性(FWOP)和延迟(SWOP)心脏保护作用。RPAC可显著降低缺血/再灌注诱导的LDH、CK释放和心肌梗死面积。在全脑缺血/再灌注前10分钟给予l-NAME(硝基-l-精氨酸-甲基lester) (10mg kg - 1静脉注射)、氨基胍(150mg kg - 1静脉注射)、氨基胍(300mg kg - 1静脉注射)、s -甲基异硫脲(3mg kg - 1静脉注射)和1400W (1mg kg - 1静脉注射),均未产生显著效果。RPAC后预处理氨基胍(150 mg kg−1 s.c.)、氨基胍(300 mg kg−1 s.c.)、s -甲基异硫脲(3 mg kg−1 I.V.)和1400W (1 mg kg−1 I.V.)对RPAC诱导的LDH、CK和梗死面积的急性降低没有显著影响,而l-NAME (10 mg kg−1 I.V.)增加了RPAC诱导的LDH、CK和梗死面积的降低。最有趣的观察结果是关于延迟RPAC,其中所有NOS抑制剂的预处理都减弱了RPAC诱导的LDH, CK和梗死面积的降低。主要结论:srpac具有与经典或其他远端缺血预处理刺激相似的心脏保护作用。此外,RPAC晚期或延迟期已介导iNOS,而它不参与急性RPAC。
{"title":"Remote preconditioning by aortic constriction: Does it afford cardioprotection similar to classical or other remote ischaemic preconditioning? Role of inducible nitric oxide synthase","authors":"Ashish Kumar Sharma ,&nbsp;Arshee Munajjam ,&nbsp;Bhawna Vaishnav ,&nbsp;Richa Sharma ,&nbsp;Kunal Kishore ,&nbsp;Ashok Sharma ,&nbsp;Akash Sharma ,&nbsp;Divya Sharma ,&nbsp;Rita Kumari ,&nbsp;Ashish Tiwari ,&nbsp;B.P. Srinivasan ,&nbsp;Shyam Sunder Agarwal","doi":"10.1016/j.cvdpc.2010.12.001","DOIUrl":"10.1016/j.cvdpc.2010.12.001","url":null,"abstract":"<div><h3>Purpose of the research</h3><p>Does remote preconditioning by aortic constriction (RPAC) afford cardioprotection similar to classical or other remote ischaemic preconditioning stimulus? Moreover, the study was also designed to investigate the role of inducible nitric oxide synthase (iNOS) in remote preconditioning by aortic constriction. There are sufficient evidence that ‘ischaemic preconditioning’ has surgical applications and affords clinically relevant cardioprotection. Transient occlusion of the circumflex artery, renal artery, limb artery or mesenteric artery preconditions the myocardium against ischaemia/reperfusion injury in case of ischaemic heart disease leading to myocardial infarction. Here, the abdominal aorta was selected to produce RPAC.</p></div><div><h3>The principal results</h3><p>Four episodes of ischaemia/reperfusion of 5<!--> <!-->min each to the abdominal aorta produced RPAC by assessment of infarct size, lactate dehydrogenase (LDH) and creatine phosphokinase (CK). These studies suggest RPAC produced acute (FWOP) and delayed (SWOP) cardioprotective effects. RPAC demonstrated a significant decrease in ischaemia/reperfusion-induced release of LDH, CK and extent of myocardial infarct size. <span>l</span>-NAME (nitro-<span>l</span>-arginine-methylester) (10<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.), aminoguanidine (150<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), aminoguanidine (300<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), S-methyl isothiourea (3<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) and 1400W (1<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) administered 10<!--> <!-->min. before global ischaemia/reperfusion produced no marked effect. Aminoguanidine (150<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), aminoguanidine (300<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> s.c.), S-methyl isothiourea (3<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) and 1400W (1<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) pre-treatment after RPAC produced no significant effect on acute RPAC-induced decrease in LDH, CK and infarct size, whereas <span>l</span>-NAME (10<!--> <!-->mg<!--> <!-->kg<sup>−1</sup> I.V.) increased RPAC-induced decrease in LDH, CK and infarct size. The most interesting observation is with respect to delayed RPAC, where all NOS inhibitors’ pre-treatment attenuate RPAC-induced decrease in LDH, CK and infarct size.</p></div><div><h3>Major conclusions</h3><p>RPAC affords cardioprotection similar to classical or other remote ischaemic preconditioning stimulus. Moreover, late or delayed phase of RPAC has been mediated iNOS, whereas it is not involved in acute RPAC.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 1","pages":"Pages 15-33"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2010.12.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73547723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Medication adherence and associated barriers in hypertension management in India 印度高血压管理中的药物依从性和相关障碍
Pub Date : 2011-01-01 DOI: 10.1016/j.cvdpc.2010.11.001
Dennis Thomas , N.K. Meera , K. Binny , M. Sonal Sekhar , Githa Kishore , Salini Sasidharan

Hypertension is inadequately controlled in most patients due to poor adherence to treatment. Not much is known about the underlying reasons for poor adherence. The main objective of this study was to assess medication adherence in hypertensive patients and to identify the main barriers associated with medication adherence. A questionnaire-based survey was conducted in the medicine outpatient department of Kempe Gowda Institute of Medical Sciences and Research Centre, Bangalore, India. Self reported adherence was measured by using a short validated questionnaire and detailed patient interviews. Of the 608 patients participated, non-adherence was found in 49.67% of patients. Belief barrier was reported in 39.14% patients. Access barrier and recall barrier were reported by 82.57% and 62.17%, respectively. 78.62% of patients reported that it is difficult to pay for the medication and 54.93% indicated that it is difficult to get a refill on time. It was concluded that about half of the Indian patients studied were not adherent to their antihypertensive regimen and this might result in poor blood pressure control. Non-adherence to hypertension management remains a major limiting factor among Indians in the effective control of hypertension and in the prevention of cardiovascular diseases.

由于治疗依从性差,大多数患者的高血压得不到充分控制。人们对不良依从性的根本原因知之甚少。本研究的主要目的是评估高血压患者的药物依从性,并确定与药物依从性相关的主要障碍。在印度班加罗尔Kempe Gowda医学科学和研究中心医学门诊部进行了一项基于问卷的调查。自我报告的依从性通过使用简短的有效问卷和详细的患者访谈来测量。在608名患者中,49.67%的患者出现不依从性。39.14%的患者存在信念障碍。进入障碍和回忆障碍的比例分别为82.57%和62.17%。78.62%的患者表示难以支付药费,54.93%的患者表示难以按时补药。结论是,大约一半的印度患者没有坚持他们的降压方案,这可能导致血压控制不佳。不坚持高血压管理仍然是印度人有效控制高血压和预防心血管疾病的主要限制因素。
{"title":"Medication adherence and associated barriers in hypertension management in India","authors":"Dennis Thomas ,&nbsp;N.K. Meera ,&nbsp;K. Binny ,&nbsp;M. Sonal Sekhar ,&nbsp;Githa Kishore ,&nbsp;Salini Sasidharan","doi":"10.1016/j.cvdpc.2010.11.001","DOIUrl":"https://doi.org/10.1016/j.cvdpc.2010.11.001","url":null,"abstract":"<div><p>Hypertension is inadequately controlled in most patients due to poor adherence to treatment. Not much is known about the underlying reasons for poor adherence. The main objective of this study was to assess medication adherence in hypertensive patients and to identify the main barriers associated with medication adherence. A questionnaire-based survey was conducted in the medicine outpatient department of Kempe Gowda Institute of Medical Sciences and Research Centre, Bangalore, India. Self reported adherence was measured by using a short validated questionnaire and detailed patient interviews. Of the 608 patients participated, non-adherence was found in 49.67% of patients. Belief barrier was reported in 39.14% patients. Access barrier and recall barrier were reported by 82.57% and 62.17%, respectively. 78.62% of patients reported that it is difficult to pay for the medication and 54.93% indicated that it is difficult to get a refill on time. It was concluded that about half of the Indian patients studied were not adherent to their antihypertensive regimen and this might result in poor blood pressure control. Non-adherence to hypertension management remains a major limiting factor among Indians in the effective control of hypertension and in the prevention of cardiovascular diseases.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 1","pages":"Pages 9-13"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2010.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91687953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 63
Medication adherence and associated barriers in hypertension management in India 印度高血压管理中的药物依从性和相关障碍
Pub Date : 2011-01-01 DOI: 10.1016/J.CVDPC.2010.11.001
T. Dennis, N. Meera, K. Binny, M. Sekhar, G. Kishore, S. Sasidharan
{"title":"Medication adherence and associated barriers in hypertension management in India","authors":"T. Dennis, N. Meera, K. Binny, M. Sekhar, G. Kishore, S. Sasidharan","doi":"10.1016/J.CVDPC.2010.11.001","DOIUrl":"https://doi.org/10.1016/J.CVDPC.2010.11.001","url":null,"abstract":"","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"16 1","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81697774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 64
The mosaic of CVD risk factors – A study on 10,000 Pakistani cardiac patients 心血管疾病危险因素的马赛克-对10,000名巴基斯坦心脏病患者的研究
Pub Date : 2011-01-01 DOI: 10.1016/J.CVDPC.2010.10.002
A. Kayani, Nausheen Bakht, R. Munir, Irum Abid
{"title":"The mosaic of CVD risk factors – A study on 10,000 Pakistani cardiac patients","authors":"A. Kayani, Nausheen Bakht, R. Munir, Irum Abid","doi":"10.1016/J.CVDPC.2010.10.002","DOIUrl":"https://doi.org/10.1016/J.CVDPC.2010.10.002","url":null,"abstract":"","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"30 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76892266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
The mosaic of CVD risk factors – A study on 10,000 Pakistani cardiac patients 心血管疾病危险因素的马赛克-对10,000名巴基斯坦心脏病患者的研究
Pub Date : 2011-01-01 DOI: 10.1016/j.cvdpc.2010.10.002
Azhar Mahmood Kayani , Nausheen Bakht , Rubab Munir , Irum Abid

Objective

To determine the cardiovascular disease risk factor profile of Pakistani patients.

Material and methods

In this cross sectional study, 10,000 patients with CVD were recruited. This 1 year study was conducted in the outpatient department of Armed Forces Institute of Cardiology/National Institute of Heart Diseases (AFIC-NIHD), which provides primary, secondary and tertiary cardiac care to patients from all over the country. The CVD risk factors studied included hypertension, diabetes, dyslipidemia, obesity, smoking, alcohol intake, inactivity, eating <5 portions of fruits and/or vegetables per day.

Results and discussion

Of the study participants 73.5% were males while 26.5% were females. Their average age was 53.83 ± 14.18 years and 51.68 ± 15.83 years, respectively. The frequency of premature CVD was 27.2% in males and 49.1% in females. 46.9% males and 77.4% females had abdominal obesity, 15.6% men and 1.9% women being current smokers. Blood cholesterol levels were >200 mg/dl in 10% of all study subjects. In a decreasing order, poor lipid values were seen for HDL, VLDL, TG, cholesterol, LDL and LDL/HDL. Diabetes and hypertension affected 18.5% and 8% study subjects, respectively. Mean BMI was 21.02 kg/m2 in men and 22.41 kg/m2 in women. 64.5% participants did not take five or more servings of fruits and/or vegetables per day. 66% males and 68% females were physically inactive.

Conclusion

Risk factors in Pakistani patients can be rank ordered as abdominal obesity, eating <5 portions of fruits and/or vegetables per day, HDL, physical inactivity, diabetes, VLDL, TG, smoking, cholesterol, hypertension, obesity, LDL, LDL/HDL and alcohol.

目的了解巴基斯坦心血管疾病危险因素。材料和方法在这项横断面研究中,招募了10,000名心血管疾病患者。这项为期一年的研究是在军队心脏病研究所/国家心脏病研究所(AFIC-NIHD)的门诊部进行的,该研究所为来自全国各地的患者提供初级、二级和三级心脏病护理。研究的心血管疾病风险因素包括高血压、糖尿病、血脂异常、肥胖、吸烟、饮酒、缺乏运动、每天吃5份水果和/或蔬菜。研究参与者中73.5%为男性,26.5%为女性。平均年龄分别为53.83±14.18岁和51.68±15.83岁。男性早发性心血管疾病的发生率为27.2%,女性为49.1%。46.9%的男性和77.4%的女性患有腹部肥胖,15.6%的男性和1.9%的女性目前吸烟。10%的研究对象的血液胆固醇水平为200毫克/分升。HDL、VLDL、TG、胆固醇、LDL和LDL/HDL的脂质值依次下降。糖尿病和高血压分别影响18.5%和8%的研究对象。男性的平均BMI为21.02 kg/m2,女性为22.41 kg/m2。64.5%的参与者每天没有吃五份或更多的水果和/或蔬菜。66%的男性和68%的女性缺乏运动。结论巴基斯坦患者的危险因素依次为腹部肥胖、每天吃5份水果和/或蔬菜、高密度脂蛋白、缺乏运动、糖尿病、VLDL、TG、吸烟、胆固醇、高血压、肥胖、低密度脂蛋白、低密度脂蛋白/高密度脂蛋白和酒精。
{"title":"The mosaic of CVD risk factors – A study on 10,000 Pakistani cardiac patients","authors":"Azhar Mahmood Kayani ,&nbsp;Nausheen Bakht ,&nbsp;Rubab Munir ,&nbsp;Irum Abid","doi":"10.1016/j.cvdpc.2010.10.002","DOIUrl":"https://doi.org/10.1016/j.cvdpc.2010.10.002","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the cardiovascular disease risk factor profile of Pakistani patients.</p></div><div><h3>Material and methods</h3><p>In this cross sectional study, 10,000 patients with CVD were recruited. This 1<!--> <!-->year study was conducted in the outpatient department of Armed Forces Institute of Cardiology/National Institute of Heart Diseases (AFIC-NIHD), which provides primary, secondary and tertiary cardiac care to patients from all over the country. The CVD risk factors studied included hypertension, diabetes, dyslipidemia, obesity, smoking, alcohol intake, inactivity, eating &lt;5 portions of fruits and/or vegetables per day.</p></div><div><h3>Results and discussion</h3><p>Of the study participants 73.5% were males while 26.5% were females. Their average age was 53.83<!--> <!-->±<!--> <!-->14.18<!--> <!-->years and 51.68<!--> <!-->±<!--> <!-->15.83<!--> <!-->years, respectively. The frequency of premature CVD was 27.2% in males and 49.1% in females. 46.9% males and 77.4% females had abdominal obesity, 15.6% men and 1.9% women being current smokers. Blood cholesterol levels were &gt;200<!--> <!-->mg/dl in 10% of all study subjects. In a decreasing order, poor lipid values were seen for HDL, VLDL, TG, cholesterol, LDL and LDL/HDL. Diabetes and hypertension affected 18.5% and 8% study subjects, respectively. Mean BMI was 21.02<!--> <!-->kg/m<sup>2</sup> in men and 22.41<!--> <!-->kg/m<sup>2</sup> in women. 64.5% participants did not take five or more servings of fruits and/or vegetables per day. 66% males and 68% females were physically inactive.</p></div><div><h3>Conclusion</h3><p>Risk factors in Pakistani patients can be rank ordered as abdominal obesity, eating &lt;5 portions of fruits and/or vegetables per day, HDL, physical inactivity, diabetes, VLDL, TG, smoking, cholesterol, hypertension, obesity, LDL, LDL/HDL and alcohol.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 1","pages":"Pages 1-7"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2010.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91642288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
期刊
Cvd Prevention and Control
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1